| 764598 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
461 Updated PFS analysis of toripalimab with anlotinib and chemotherapy as first-line therapy in patients with extensive-stage small-cell lung cancer (ES-SCLC) |
2021-11-01 |
10.1136/jitc-2021-sitc2021.461 |
Luo Hao, Jian Dan, Feng Yan, Zhong Li, Chen Qian, Guan Wei, Zhang Shiheng, Luo Jiamin, Yang Xueqin, Gong Kan, Xiong Yanli, Li Mengxia, Xu Mingfang, Pu Yu, Zhao Liang, Qian Chengyuan, Dai Nan, Wang Dong |
| 764597 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
458 First phase 2 results of autologous tumor-infiltrating lymphocyte (TIL; LN-145) monotherapy in patients with advanced, immune checkpoint inhibitor-treated, non-small cell lung cancer (NSCLC) |
2021-11-01 |
10.1136/jitc-2021-sitc2021.458 |
Schoenfeld Adam, Lee Sylvia, Paz-Ares Luis, Doger Bernard, Gettinger Scott, Haefliger Simon, Orcurto Angela, Sukari Ammar, Papa Sophie, Rodriguez Moreno Juan Francisco, Finckenstein Friedrich Graf, Jagasia Madan, Fiaz Rana, Sulur Giri, Chen Guang, Gontcharova Viktoria, He Kai |
| 764596 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
334 Phase I study of safety and activity of personalized neoantigen-based vaccines in combination with tumor treating fields for newly diagnosed glioblastoma patients |
2021-11-01 |
10.1136/jitc-2021-sitc2021.334 |
Hormigo Adilia, Kodysh Julia, Bozkus Cansu Cimen, Saxena Mansi, Meseck Marcia, Rubinsteyn Alexander, Timothy O, Thin Tin Htwe, Brody Rachel, Mandeli John, Bhardwaj Nina |
| 764595 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
332 Tumor collection and establishment of tumor-initiating cell cultures as antigen source for AV-GBM-1 dendritic cell vaccines for a phase II trial in patients with newly diagnosed glioblastoma |
2021-11-01 |
10.1136/jitc-2021-sitc2021.332 |
Duma Christopher, Bota Daniela, Hsu Frank, Piccioni David, LaRocca Renato, Kesari Santosh, Abedi Mehrdad, Carrillo Jose, Aiken Robert, Kong Xiao-Tang, Taylor Thomas, Hsieh Candace, Nistor Gabriel, Dillman Robert |
| 764594 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
402 Pegasus GI, a platform study of SAR444245 (THOR-707, a pegylated recombinant non-alpha IL2) with anti-cancer agents of participants with advanced and metastatic gastrointestinal cancer |
2021-11-01 |
10.1136/jitc-2021-sitc2021.402 |
Harris William, Baakili Adyb, Kang Yoon-Koo, Demers Brigitte, Menas Fatima-Zohra, Gosselin Alice, Abbadessa Giovanni, Cutsem Eric Van |
| 764593 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
400 Persistence and tissue distribution of agent-797 – a native allogeneic iNKT cell-therapy drug product |
2021-11-01 |
10.1136/jitc-2021-sitc2021.400 |
Purbhoo Marco, Yigit Burcu, Moskowitz Darrian, Lim Min, Shapiro Irina, Alsaraby Ayat, Michelet Xavier, Dijk Marc Van |
| 764592 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
399 A phase II study of nivolumab, ipilimumab, plus androgen receptor blockade with bicalutamide to enhance thymic T-cell production and immunotherapy response in metastatic breast cancer |
2021-11-01 |
10.1136/jitc-2021-sitc2021.399 |
Page David, Collins Krystle, Chun Brie, Sun Zhaoyu, Koguchi Yoshinobu, Redmond William, Martel Maritza, Wu Yaping, Moxon Nicole, Mellinger Staci, Urba Walter, Gucalp Ayca, Traina Tiffany |
| 764591 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
331 Tumor markers associated with increased survival in a phase II trial of dendritic cell/tumor-initiating-cell vaccine AV-GBM-1 in patients with newly diagnosed glioblastoma |
2021-11-01 |
10.1136/jitc-2021-sitc2021.331 |
Bota Daniela, Piccioni David, Duma Christopher, LaRocca Renato, Kesari Santosh, Carrillo Jose, Hsu Frank, Kong Xiao-Tang, Abedi Mehrdad, Aiken Robert, Taylor Thomas, Hsieh Candace, Nistor Gabriel, Dillman Robert |
| 764590 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
330 Integration of molecular cancer classification and next-generation sequencing to identify metastatic patients eligible for immune checkpoint inhibitors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.330 |
Mahadevan Daruka, Ma Li, Treuner Kai, Wong Jenna, Schnabel Catherine |
| 764589 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
329 Early blood cell count test (BCT) for survival prediction for non-small cell lung cancer patients treated with atezolizumab: integrated analysis of 4 multicenter clinical trials |
2021-11-01 |
10.1136/jitc-2021-sitc2021.329 |
Zhou Jian-Guo, Wong Ada Hang-Heng, Wang Haitao, Jin Su-Han, Tan Fangya, Chen Yu-Zhong, He Si-si, Shen Gang, Frey Benjamin, Fietkau Rainer, Hecht Markus, Shen Bo, Ma Hu, Gaipl Udo |
